Kura Oncology (KURA) announced the first U.S. commercial sale of KOMZIFTI has been completed. Under Kura’s collaboration and license agreement with Kyowa Kirin Co. and Kyowa Kirin Inc., this milestone triggers a $135 million payment from Kyowa Kirin to Kura, which Kura expects to receive prior to year-end. KOMZIFTI was approved by the U.S. Food and Drug Administration on November 13, 2025.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology’s Growth Potential Boosted by KOMZIFTI’s NCCN Inclusion and Competitive Advantages
- Positive Outlook on Kura Oncology: Komzii’s Approval and Safety Profile Drive Buy Rating
- Kura Oncology price target raised to $28 from $11 at Barclays
- FDA Calendar: These Are the Upcoming FDA Drug Approvals
- Kura Oncology price target raised to $30 from $29 at BofA